

## **Ascendis Pharma UK Limited – Patient Organizations – Methodological Note for 2024 reporting**

### **1 Introduction and general summary**

Ascendis Pharma UK Limited (Ascendis Pharma) is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by our core values of patients, science and passion, we use our TransCon® technology to fulfil our mission of developing new and potentially best-in-class therapies that address unmet medical needs.

As part of fulfilling this mission, we work with UK Patient Organizations (POs), and we report applicable Transfers of Value (ToVs) in alignment with the ABPI Code.

In this methodological note, we will present relevant details on our approach to reporting the ToVs provided to UK POs.

### **2 Scope of disclosure**

Ascendis Pharma will disclose ToVs provided to UK POs by Ascendis Pharma A/S and its affiliates.

### **3 Data privacy**

Ascendis Pharma UK Ltd. is committed to ensuring that personal data is processed, used, transferred and disclosed in accordance with all applicable data protection laws and regulations. For more information, please visit our website.

### **4 Methodology**

#### **4.1 Disclosure data and year**

Ascendis Pharma will disclose ToVs based on the date of payment. If the ToV is provided through a multi-year engagement or activity, please see section 4.4.

#### **4.2 Currency**

Disclosures of ToVs will be made in GBP. If payments are made in another currency, these will be manually converted to GBP when the ToV is tracked in the internal Ascendis Pharma disclosure process.

#### **4.3 Cross-border activities and payments**

Ascendis Pharma has established an internal process to ensure that activities organised across borders are conducted in a compliant manner. Therefore, no matter which legal entity within Ascendis Pharma A/S is providing the ToV to UK PO, it will be captured and disclosed accordingly.

#### **4.4 Multi-year engagements or activities**

ToVs provided as part of multi-year engagements or activities will be disclosed in the year when the individual ToV is paid.

## 4.5 Tax

ToV amounts will be disclosed excluding tax, if administratively possible.

## 4.6 Direct and indirect Transfers of Value

Direct ToVs are payments made by Ascendis Pharma or its affiliates to the UK PO.

Indirect ToVs are payments made by a third party on behalf of Ascendis Pharma to the UK PO. Applicable direct and indirect ToVs will be disclosed.

## 4.7 Data Retention

The disclosed information will be made public for three years counting from the day of the disclosure.

The disclosed information and related records will be retained for a minimum of five years.

## 5 Transfer of Value categories

Category	Description
<b>Grants and donations</b>	Grants and donations are provided to UK POs with the purpose of supporting healthcare and education.  Ascendis Pharma has established an internal process for review and approval of all requests for grants and donations. This process includes a compliance review aimed to ensure that applicable requirements are followed, including Clause 23 in the ABPI Code. See the Ascendis Pharma definition of grants and donations in section 6.
<b>Contracted services</b>	Ascendis Pharma may contract UK PO representatives to provide services in alignment with clause 24, e.g., to collect input not available internally in Ascendis Pharma. The fees and related expenses will be disclosed separately, if possible.
<b>Sponsorships of events</b>	Ascendis Pharma sponsors events organised by UK POs. Such sponsorships will be disclosed as sponsorship agreements under the name of the ultimate beneficiary.

## 6 Ascendis Pharma definitions

Term	Definition
<b>Ascendis Pharma</b>	Ascendis Pharma A/S and its affiliates worldwide.
<b>Cross-border</b>	An interaction with Healthcare Professionals, Healthcare Organisations, Patient Organisations or Patients who are residents of another country than the Ascendis Pharma organising/sponsoring entity.
<b>Donation</b>	A voluntary contribution provided without receiving any benefit, compensation or advantage in return.

	The mere display of a logo or name is not considered a benefit.
<b>Grant</b>	Monetary contributions given for the purpose of advancing healthcare, scientific research or education without the intent of receiving any benefit in return. The mere display of a logo or name is not considered a benefit. Grant requests must be unsolicited.
<b>Patient Organisation (PO)</b>	Organisation (including the umbrella organisation to which they belong), mainly composed of Patients and/or caregivers that represent and/or support the needs of Patients and/or caregivers. This includes non-profit, profit and/or consumer organisations.
<b>Personal data</b>	Personal data means any information relating to an identified or identifiable natural person “Data Subject”; an identifiable person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, on-line identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that person. Personal data includes both data that relate to an individual acting as a private person and to an individual acting as a professional, e.g., a business relation.
<b>Transfers of Value (ToVs)</b>	Any direct or indirect value provided (on behalf of Ascendis Pharma) whether monetary or not. This includes but is not limited to payments of fees for services, registration fees, travel and the provision of hospitality.